| Status: Superseded | ||
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED JUNE 2017. Refer to HST5: Eliglustat for treating type 1 Gaucher disease for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. AWMSG documentation provided for reference only. |
||
|
||
Medicine details |
||
| Medicine name | eliglustat tartrate (Cerdelga®) | |
| Formulation | 84 mg capsule | |
| Reference number | 2016 | |
| Indication | Long-term treatment of adult patients with Gaucher disease type 1 (GD1), who are CYP2D6 poor metabolisers (PMs), intermediate metabolisers (Ims) or extensive metabolisers (EMs) |
|
| Company | Genzyme Therapeutics | |
| BNF chapter | Nutrition & blood | |
| Assessment type | Non-submission | |
| Status | Superseded | |
| Ratification by Welsh Government | 15/05/2015 | |
| Date of issue | 20/05/2015 | |
| NICE guidance | ||
| Commercial arrangement | PAS | |